COMPLERA Drug Patent Profile
✉ Email this page to a colleague
When do Complera patents expire, and what generic alternatives are available?
Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has three hundred and thirty-four patent family members in fifty-two countries.
The generic ingredient in COMPLERA is emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Complera
Complera was eligible for patent challenges on May 20, 2015.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 14, 2033. This may change due to patent challenges or generic licensing.
There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COMPLERA?
- What are the global sales for COMPLERA?
- What is Average Wholesale Price for COMPLERA?
Summary for COMPLERA
| International Patents: | 334 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Clinical Trials: | 6 |
| Patent Applications: | 89 |
| Drug Prices: | Drug price information for COMPLERA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COMPLERA |
| What excipients (inactive ingredients) are in COMPLERA? | COMPLERA excipients list |
| DailyMed Link: | COMPLERA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for COMPLERA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for COMPLERA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ottawa Hospital Research Institute | Phase 3 |
| Gilead Sciences | Phase 3 |
| CIHR Canadian HIV Trials Network | Phase 3 |
Pharmacology for COMPLERA
Paragraph IV (Patent) Challenges for COMPLERA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| COMPLERA | Tablets | emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate | 200 mg/25 mg/ 300 mg | 202123 | 1 | 2015-05-20 |
US Patents and Regulatory Information for COMPLERA
COMPLERA is protected by seven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of COMPLERA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting COMPLERA
Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
HIV inhibiting pyrimidines derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Compositions and methods for combination antiviral therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Compositions and methods for combination antiviral therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Combinations of a pyrimidine containing NNRTI with RT inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Compositions and methods for combination antiviral therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Compositions and methods for combination antiviral therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION
Expired US Patents for COMPLERA
International Patents for COMPLERA
When does loss-of-exclusivity occur for COMPLERA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 16
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Argentina
Patent: 4500
Patent: TABLETA MULTICAPA PARA TRATAR LA INFECCION POR HIV EN UN HUMANO
Estimated Expiration: ⤷ Sign Up
Patent: 3409
Patent: COMPOSICIONES TERAPÉUTICAS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11329642
Patent: Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
Estimated Expiration: ⤷ Sign Up
Patent: 16208417
Patent: Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
Estimated Expiration: ⤷ Sign Up
Patent: 18202635
Patent: Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2013012245
Patent: composições terapêuticas compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 18097
Patent: COMPOSITIONS THERAPEUTIQUES COMPRENANT UN HYDROCHLORURE DE RILPIVIRINE ET UN FUMARATE DE TENOFOVIR DISOPROXIL (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 13001402
Patent: Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih.
Estimated Expiration: ⤷ Sign Up
China
Patent: 3491948
Patent: Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
Estimated Expiration: ⤷ Sign Up
Patent: 6511357
Patent: 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 (Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 61300
Patent: Composiciones terapéuticas que comprenden rilvipirina hcl y tenofovir disoproxil fumarato
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 130293
Patent: COMPOSICIONES TERAPÉUTICAS QUE COMPRENDEN RILPIVIRINA HCL Y TENOFOVIR DISOPROXIL FUMARATO
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0140946
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16115
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 40362
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 13012700
Patent: COMPOSICIONES TERAPÉUTICAS QUE COMPRENDEN RILPIVIRINA HCL Y TENOFOVIR DISOPROXIL FUMARATO
Estimated Expiration: ⤷ Sign Up
Patent: 19078196
Patent: COMPOSICIONES TERAPÉUTICAS QUE COMPRENDEN RILPIVIRINA HCL Y TENOFOVIR DISOPROXIL FUMARATO
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5852
Patent: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCl AND TENOFOVIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Patent: 1390651
Patent: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCL И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
Estimated Expiration: ⤷ Sign Up
Patent: 1691695
Patent: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCL И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 40362
Patent: COMPOSITIONS THÉRAPEUTIQUES COMPRENANT UN HYDROCHLORURE DE LA RILPIVIRINE ET UN FUMARATE DE TÉNOFOVIR DISOPROXIL (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRIN HCL AND TENOVOFIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Patent: 26466
Patent: Compositions thérapeutiques comprenant du rilpivirin hcl et du ténofovir disoproxil fumarate (Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 90064
Patent: 含有鹽酸利匹韋林和富馬酸替諾福韋酯的治療組合物 (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRIN HCL AND TENOVOFIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Patent: 06592
Patent: 含有鹽酸利匹韋林和富馬酸替諾福韋酯的治療組合物 (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRIN HCL AND TENOFOVIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6300
Patent: תכשירים טיפוליים המכילים רילפיבירין הידרוכלוריד ודנופוביר דיסאופרוקסיל פומאראט (Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 38851
Estimated Expiration: ⤷ Sign Up
Patent: 14500261
Estimated Expiration: ⤷ Sign Up
Patent: 15131853
Patent: リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCl AND TENOFOVIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 5604
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 7512
Patent: COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN HCL DE RILPIVIRINA Y FUMARATO DE DISOPROXILO DE TENOFOVIR. (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE.)
Estimated Expiration: ⤷ Sign Up
Patent: 13005669
Patent: COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN HCL DE RILPIVIRINA Y FUMARATO DE DISOPROXILO DE TENOFOVIR. (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 980
Patent: TERAPEUTSKE KOMPOZICIJE KOJE SADRŽE RILPIVIRIN HCL I TENOFOVIR DIZOPROKSIL FUMARAT (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 735
Patent: COMPOSITIONS THÉRAPEUTIQUES COMPRENANT UN HYDROCHLORURE DE RILPIVIRINE ET UN FUMARATE DE TÉNOFOVIR DISOPROXIL
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0729
Patent: Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 140163
Patent: COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN RILPIVIRINA HCL Y TENOFOVIR DISOPROXIL FUMARATO
Estimated Expiration: ⤷ Sign Up
Patent: 170521
Patent: COMBINACION FARMACEUTICA QUE COMPRENDE RILPIVIRINA HCL, TENOFOVIR DISOPROXIL FUMARATO Y EMTRICITABINA
Estimated Expiration: ⤷ Sign Up
Patent: 211657
Patent: COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN RILPIVIRINA HCL Y TENOFOVIR DISOPROXIL FUMARATO
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 40362
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 40362
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01400150
Patent: Composizioni terapeutiche comprendenti rilpivirinacloridrato e tenofovir disoproxil fumarato
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 691
Patent: TERAPEUTSKE KOMPOZICIJE KOJE SADRŽE RILPIVIRIN HCL I TENOVOFIR DIZOPROKSIL FUMARAT (THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRIN HCL AND TENOVOFIR DISOPROXIL FUMARATE)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 0333
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Patent: 201509521W
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Patent: 201912527X
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 40362
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1304481
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1923103
Estimated Expiration: ⤷ Sign Up
Patent: 140037799
Patent: THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 24408
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 56840
Estimated Expiration: ⤷ Sign Up
Patent: 1238612
Patent: Therapeutic compositions
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4075
Patent: БАГАТОШАРОВА ТАБЛЕТКА, ЩО МІСТИТЬ РИЛПІВІРИН HCl, ЕМТРИЦИТАБІН І ТЕНОФОВІРУ ДИЗОПРОКСИЛФУМАРАТ
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering COMPLERA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 1092698 | 包含嘧啶的 抑制劑的組合 (COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS NNRTI RT) | ⤷ Sign Up |
| New Zealand | 520502 | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ⤷ Sign Up |
| Taiwan | 200524612 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | ⤷ Sign Up |
| United Kingdom | 0004887 | ⤷ Sign Up | |
| Spain | 2923581 | ⤷ Sign Up | |
| Australia | 2005279157 | Furamate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COMPLERA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1419152 | C 2012 016 | Romania | ⤷ Sign Up | PRODUCT NAME: COMBINATIE DE RILPIVIRINA SI TOATE FORMELE ECHIVALENTETERAPEUTIC ALE ACESTEIA CUM AR FI SARURILE DE ADITIE ALE RILPIVIRINEI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREARILPIVIRINEI CU ACIDUL CLORHIDRIC, SI TENOFOVIR, IN PARTICULAR FUMARAT DE TENOFOVIRDISOPROXIL; NATIONAL AUTHORISATION NUMBER: EU/1/11/737/001, EU/1/11/737/002; DATE OF NATIONAL AUTHORISATION: 20111128; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/737/001, EU/1/11/737/002; DATE OF FIRST AUTHORISATION IN EEA: 20111128 |
| 1663240 | PA2015037,C1663240-2 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINO ARBA TERAPINIU POZIURIU PRIIMTINOS JO FORMOS, TOKIOS KAIP RILPIVIRINO DRUSKOS,ISKAITANT RILPIVIRINO HIDROCHLORIDA, TENOFOVIRO, YPAC TENOFOVIRO DIZOPROKSILIO FUMARATO, IR EMTRICITABINODERINYS; REGISTRATION NO/DATE: EU/1/11/737/001 2011-11-28, EU/1/11/737/002 20111128 |
| 1663240 | 379 5033-2016 | Slovakia | ⤷ Sign Up | PRODUCT NAME: RILPIVIRIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/TENOFOVIR-ALAFENAMID VO VSETKYCH FORMACH CHRA- NENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1112 20160623 |
| 1663240 | 132016000024787 | Italy | ⤷ Sign Up | PRODUCT NAME: ASSOCIAZIONE DI RILPIVIRINA E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE PROTETTA DAL BREVETTO DI BASE, COME SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI DI RILPIVIRINA, COMPRESO IL SUO SALE CLORIDRATO, TENOFOVIR, IN PARTICOLARE TENOFOVIR DISOPROXIL FUMARATO E EMITRICITABINA(EVIPLERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/737/001-002, 20111128 |
| 3808743 | PA2022515,C3808743 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINO ARBA FARMACINIU POZIURIU PRIIMTINOS PRIDETINES RILPIVIRINO DRUSKOS, ISKAITANT RILPIVIRINO HIDROCHLORIDO RUGSTIES DRUSKA, IR EMTRICITABINO DERINYS; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 1663240 | PA2015038,C1663240-3 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINO ARBA TERAPINIU POZIURIU PRIIMTINOS JO FORMOS, TOKIOS KAIP RILPIVIRINO DRUSKOS,ISKAITANT RILPIVIRINO HIDROCHLORIDA, IR TENOFOVIRO, YPAC TENOFOVIRO DIZOPROKSILIO FUMARATO, DERINYS; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
